<DOC>
	<DOCNO>NCT01142661</DOCNO>
	<brief_summary>The purpose study provide eribulin patient advanced breast cancer treatment option therapy request Investigator .</brief_summary>
	<brief_title>Compassionate Use Eribulin Treatment Advanced Breast Cancer Refractory All Other Marketed Therapies</brief_title>
	<detailed_description>This compassionate use program consist Pretreatment Phase Treatment Phase . Patients locally advance metastatic breast cancer fulfill eligibility criterion may treat . Safety data collect , minimal amount data also collect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion Criteria In order receive eribulin protocol , subject oncologist must document experience treat subject eribulin prior clinical study . Subjects meet follow criterion include treatment protocol : 1 . Recurrent , locally advanced metastatic breast cancer progress last anticancer therapy . 2 . Prior treatment , ineligibility , commercial unavailability follow therapy : Anthracyclines , taxanes , capecitabine . Ixabepilone country agent market . Trastuzumab Her2 positive disease . Hormonal therapy hormone receptorpositive disease . All marketed therapy , eg , gemcitabine vinorelbine , use treatment advance breast cancer . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 4 . Serum creatinine &lt; /= 2.0 mg/dL creatinine clearance &gt; /= 40 mL/min accord Cockcroft Gault formula . 5 . Absolute neutrophil count &gt; /= 1.5 x 10^9/L , hemoglobin &gt; /= 10 g/dL ( corrected growth factor transfusion ) , platelet count &gt; /= 100 x 10^9/L . 6 . Total bilirubin &lt; /= 1.5 x upper limit normal ( ULN ) . Alkaline phosphatase ( AP ) , alanine aminotransferase , aspartate aminotransferase &lt; /= 3 x ULN ( &lt; /= 5 x ULN case liver metastasis ) . In case AP &gt; 3 x ULN ( absence liver metastasis ) &gt; 5 x ULN ( presence liver metastasis ) AND subject also know bone metastasis , liver specific AP must separate total use ass liver function instead total AP . 7 . Are willing able comply aspect treatment protocol . 8 . Provide write informed consent . 9 . Females , age &gt; /= 18 year . 10 . Female subject childbearing potential must agree abstinent use highly effective method contraception ( eg , condom + spermicide , condom + diaphragm spermicide , intrauterine device , vasectomised partner ) start least one menstrual cycle prior start eribulin throughout entire treatment period 30 day ( longer appropriate ) last dose eribulin . Those woman use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . Perimenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Exclusion Criteria Subjects meet follow criterion exclude participation treatment protocol : 1 . Eligible eribulin study open region . 2 . Existing anticancer therapyrelated toxicity Grade &gt; /= 2 , except alopecia Grade 2 neuropathy acceptable . 3 . History congestive heart failure New York Heart Association Classification &gt; II , unstable angina , myocardial infarction within past 6 month , serious cardiac arrhythmia . 4 . Electrocardiogram QTc interval &gt; /= 500 msec base upon Bazett 's formula ( QTcB ) . 5 . The Investigator believe subject medically unfit receive eribulin unsuitable reason . 6 . Females pregnant ( positive BhCG test ) breastfeeding . 7 . Subject hypersensitivity eribulin excipients . 8 . Subjects brain subdural metastasis eligible , unless complete local therapy discontinue use corticosteroid indication least 4 week start treatment treatment protocol . Any sign ( eg , radiologic ) and/or symptom brain metastasis must stable least 4 week start treatment protocol . 9 . Any history concomitant medical condition , opinion Investigator , would compromise subject 's ability safely complete treatment protocol . 10 . Subjects know human immunodeficiency virus positive neutropenia cause eribulin treatment may make subject particularly susceptible infection . 11 . Subjects meningeal carcinomatosis . 12 . Pulmonary lymphangitic involvement result pulmonary dysfunction require active treatment , include use oxygen . 13 . Subjects receive follow treatment within specified period start treatment : Any investigational drug , chemotherapy , radiation , biological target therapy within 2 week . Hormonal therapy within 1 week .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Advanced breast cancer refractory commercially available therapy</keyword>
</DOC>